Nebraska helps secure $720 million settlement from eight opioid drug manufacturers

LINCOLN, Neb. (KLKN) — The Nebraska Attorney General’s Office announced a $720 million national settlement with eight opioid drug makers.

In a press release on Friday, the attorney general’s office said these drug manufacturers worsened the nationwide opioid crisis.

Based on the overwhelming participation of the Attorneys General across the country, all eight defendants agreed to proceed with a sign-on period for local governments.

Nebraska is eligible to receive more than $3 million as a result of these settlements.

• Mylan (now part of Viatris): $284,447,916 paid over nine years
• Hikma: $95,818,293 paid over one to four years
• Amneal: $71,751,010 paid over 10 years
• Apotex: $63,682,369 paid in a single year
• Indivior: $38,022,450 paid over four years
• Sun: $30,992,087 paid over one to four years
• Alvogen: $18,680,162 paid in a single year
• Zydus: $14,859,220 paid in a single year

In addition to these payments, several of the settlements allow states to receive free pharmaceutical products or cash in lieu of this product.

Seven of the companies — not including Indivior — are prohibited from promoting or marketing opioids and opioid products.

They are also expelled from making or selling any product that contains more than 40 mg of oxycodone per pill.

The seven companies have agreed to put in place a monitoring system for suspicious orders.

Indivior has agreed to not manufacture or sell opioid products for the next 10 years, but it will be able to continue marketing and selling medications to treat opioid use disorder.

The settlements were negotiated by North Carolina, California, Colorado, Illinois, New York, Oregon, Tennessee, Utah and Virginia.